Singapore, 18 August 2010 – Biosensors International Group, Ltd. (“Biosensors”, “Company”, Bloomberg: BIG SP) today announced that it had received approval for its BioMatrix™ drug-eluting stent system from the Department of Health in Taiwan.
“We are delighted to have obtained regulatory approval for sale of BioMatrix in Taiwan, an important regional market with a high rate of coronary stent usage,” said Jeffrey B. Jump, President and CEO of Biosensors. “This is further confirmation of the proven safety and efficacy of our products, and reflects our ongoing commitment to expanding treatment options for physicians and improving quality of life for patients.”
The BioMatrix drug-eluting stent system received CE Mark approval in January 2008 and is currently commercially available in more than 70 markets around the world.
Tencent bounces back: What to know about China’s tech giant
-
About Tencent (SGX: HTCD): A Global Leader in Digital Services Established
in 1998, Tencent has become one of the most recognised companies in China
and ...
5 hours ago
No comments:
Post a Comment